Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis

• Conditions: Hepatocellular Carcinoma; Cirrhosis

• Registration Number: NCT06624189
• Lead Sponsor: NYU Langone Health

Brief Summary

The research team will evaluate the effectiveness of an auto-pended bot liver ultrasound order that will prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-10-01
• Study First Submitted QC: 2024-10-01
• Study First Posted: 2024-10-02
• Study Start: 2024-11-20
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-08
• Last Update Posted: 2025-04-09
• Primary Completion: 2026-04-24
• Study Completion: 2026-07-24

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• cirrhosis diagnosis,
• 6 months or more after since most recent imaging.

Exclusion Criteria

• previous liver transplant,
• HCC diagnosis,
• receiving hospice care,
• completed external imaging in the past 6 months.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of Participants for whom the Physician Completed Ordering of the Pending Liver Ultrasound	Day 1

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants with Completed Liver Ultrasound Imaging	Day 1
HCC Diagnosis Rate from Completed Liver Ultrasound Imaging	Day 1

Trial Locations

Locations (1)

NYU Langone Health; 🇺🇸 New York, New York, United States